Status:

COMPLETED

The Impact of Sarcopenia on COPD Exacerbation Admission Outcome and Further Exacerbation Risk

Lead Sponsor:

Far Eastern Memorial Hospital

Conditions:

Sarcopenia

COPD Exacerbation

Eligibility:

All Genders

45+ years

Brief Summary

Chronic obstructive pulmonary disease (COPD) is more prevalent and has more impact on health status because of progressive air pollution, tobacco smoking and aging society. The COPD prevalence investi...

Eligibility Criteria

Inclusion

  • Inclusion criteria: Patients more than 45 years-old, were admitted due to COPD exacerbation.
  • COPD exacerbation criteria:
  • acute worsening respiratory symptoms without any other causes, And
  • Smoking more than 15 pack-years or the history of noxious gas exposure, And
  • Spirometry reports suggests obstructive ventilatory defect (FEV1/FVC \<0.7) or
  • Attending physicians diagnose as COPD by clinical parameters if spirometry data are not available while enrolling.
  • Definite COPD exacerbation: fulfill 1、2、3 Probable COPD exacerbation: fulfill 1、2、4
  • Exclusion criteria:
  • Significant fluid retention such as edema, pleural effusion or ascites,
  • Patients with permanent pacemaker or implantable cardioverter defibrillator ,
  • Morbid obesity with BMI \>34

Exclusion

    Key Trial Info

    Start Date :

    January 31 2018

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    June 21 2020

    Estimated Enrollment :

    43 Patients enrolled

    Trial Details

    Trial ID

    NCT04885933

    Start Date

    January 31 2018

    End Date

    June 21 2020

    Last Update

    May 13 2021

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Far Eastern Memorial Hospital

    New Taipei City, Taiwan, 220

    The Impact of Sarcopenia on COPD Exacerbation Admission Outcome and Further Exacerbation Risk | DecenTrialz